Efinopegdutide (JNJ-64565111
In a Phase II trial (NCT01398748) on PD, intranasal GSH at doses of 300 mg/day and 600 mg/day showed nonsignificant trends toward motor improvement, with slight reductions in total and motor Unified Parkinsons Disease Rating Scale (UPDRS) scores compared to placebo (total UPDRS: 5.3 and 4.3 vs
You have tried oral supplements and your labs still come back showing low nutrient markers
Current areas of scientific investigation include ghrelin receptor binding and selectivity studies, growth hormone secretagogue signaling analysis, intracellular calcium mobilization research, endocrine signaling pathway investigation, receptor activation kinetics studies, and peptide signaling network analysis
FDA-approved peptides with a prescription are completely legal
13, 823881 22 ChenN.HuY.LiW